Table 2.
Baseline patient characteristics
| Characteristic | Total number | Cytotoxic trials | Targeted trials |
|---|---|---|---|
| Enrolled patients, n | 2,713 | 1,010 | 1,703 |
| Patients evaluable for toxicity, n (%) | 2,471 (91) | 918 (91) | 1,553 (91) |
| Patients evaluable for response, n (%) | 2,143 (79) | 725 (72) | 1,418 (83) |
| Male patients, n (%) | 1,471 (54) | 532 (53) | 939 (55) |
| Age, median/trial (range), yearsa | 11 (3–21) | 10 (5–21) | 12 (3–19) |
| Prior regimens: median/trial (range) | 2 (0–9) | 2 (0–9) | 2 (9–6) |
| Prior radiationb | |||
| Yes, n (%) | 941 (35) | 289 (29) | 652 (38) |
| Unavailable | 57 studies | 29 studies | 28 studies |
| Prior stem cell transplantationb | |||
| Yes, n (%) | 341 (13) | 86 (9) | 255 (15) |
| Unavailable | 77 studies | 35 studies | 42 studies |
a
Age represents the median age reported in the trial and thus is reported as a median and range of the median ages per trial.
b
The number of patients who had received prior radiation or who had undergone prior stem hematopoietic stem cell transplant was difficult to assess as only a minority of studies reported these data.